Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 20Lymphoma, B-Cell, Marginal Zone 7Stomach Neoplasms 6Lymphoma 5Neoplasms, Plasma Cell 4Recurrence 3Dyspepsia 3Peptic Ulcer 2Gastritis 2Skin Neoplasms 1Pseudomyxoma Peritonei 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Infections 1Helicobacter Infections 1Familial primary gastric lymphoma 1Chemotherapy Effect 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1B-cell Malignancies 1Atrophy 1Appendiceal Neoplasms 1

Interventions

zanubrutinib 3tislelizumab 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1Voriconazole 1INCB039110 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × B-cell Malignancies × Clarithromycin × Clear all
NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

BeiGene

Phase 1 Completed
26 enrolled 20 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡